methotrexate has been researched along with Non-alcoholic Fatty Liver Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Cheema, HI; Dranoff, JA; Haselow, D | 1 |
| Arias-de la Rosa, I; Barbarroja, N; Collantes-Estévez, E; Cuesta-López, L; López-Pedrera, C; Pérez-Sánchez, C; Ruiz-Ponce, M | 1 |
| Aubin, F; Avouac, J; Di Martino, V; Lioté, F; Thévenot, T; Verhoeven, DW; Verhoeven, F; Vuitton, L; Wendling, D | 1 |
| Ishiwata, S; Kuroda, M; Migita, K; Miyata, M; Ohira, H; Tasaki, K | 1 |
| Aspinall, RJ; Hamilton, J; Livesey, A; Raahimi, MM; Shipman, AR | 1 |
| Arias-de la Rosa, I; Barbarroja, N; Barranco, A; Collantes-Estévez, E; Cuesta-López, L; Escudero-Contreras, A; Gahete, MD; Herman-Sánchez, N; López-Medina, C; López-Montilla, MD; López-Pedrera, C; Lucendo, AJ; Navarro, P; Ortiz-Buitrago, P; Pérez-Sánchez, C; Ruiz-Ponce, M | 1 |
| Hu, Z; Jenkins, B; Koulman, A; Lenaerts, AS; Liang, TJ; Morell, CM; Park, SB; Tilson, SG; Vallier, L | 1 |
| Alazawi, W; Cho, W; Shetty, A; Syn, WK | 1 |
| Arima, N; Fujiyama, S; Ito, M; Kamo, Y; Mori, S; Ueki, Y | 1 |
| Bigi, L; Conti, A; Lasagni, C; Pellacani, G | 1 |
| Pais, R; Ratziu, V; Rusu, E | 1 |
| Chan, GY; Koh, ET; Leong, KP; Sakthiswary, R; Thong, BY | 1 |
| Anumol, T; Canet, MJ; Cherrington, NJ; Clarke, JD; Goedken, MJ; Hardwick, RN; Lake, AD; Merrell, MD; Snyder, SA; Street, SM | 1 |
| Cherrington, NJ; Coen, M; Goedken, MJ; Hardwick, RN; Holmes, E; Jin, Z; Kyriakides, M | 1 |
| Aithal, GP; Dawwas, MF | 1 |
| Ferrazzi, A; Girolomoni, G; Gisondi, P | 1 |
| Larrain, S; Rinella, ME | 1 |
8 review(s) available for methotrexate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis.
Topics: Biopsy; Humans; Liver; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease | 2022 |
Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Inflammation; Leflunomide; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease; Risk Factors | 2022 |
Busting the myth of methotrexate chronic hepatotoxicity.
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Humans; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease | 2023 |
Liver fibrosis for the dermatologist: a review.
Topics: Dermatologists; Fibrosis; Humans; Liver Cirrhosis; Methotrexate; Non-alcoholic Fatty Liver Disease; Psoriasis | 2023 |
Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.
Topics: Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Dermatologic Agents; Diabetes Mellitus; Humans; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Risk Factors | 2017 |
The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease.
Topics: Acetaminophen; Anesthetics; Animals; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Insulin Resistance; Male; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Risk Factors; Trans-Activators; Viral Regulatory and Accessory Proteins | 2014 |
Metabolic comorbidities and psoriasis.
Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Humans; Hypertriglyceridemia; Immunosuppressive Agents; Insulin Resistance; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Obesity; Psoriasis; Risk Factors | 2010 |
A myriad of pathways to NASH.
Topics: Amiodarone; Anti-Retroviral Agents; Bacterial Infections; Cannabis; Diet; Fatty Liver; Genetic Diseases, Inborn; Glucocorticoids; Humans; Hypothyroidism; Insulin Resistance; Intestinal Diseases; Lipid Metabolism; Metabolic Syndrome; Methotrexate; Non-alcoholic Fatty Liver Disease; Occupational Diseases; Perhexiline | 2012 |
9 other study(ies) available for methotrexate and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Female; Humans; Liver Failure; Methotrexate; Non-alcoholic Fatty Liver Disease | 2023 |
Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses.
Topics: Arthritis, Psoriatic; Cross-Sectional Studies; Humans; Longitudinal Studies; Methotrexate; Non-alcoholic Fatty Liver Disease; Psoriasis; Retrospective Studies | 2023 |
Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
Topics: Cell Differentiation; Cell Line; CRISPR-Cas Systems; Ethanol; Gene Knockout Techniques; Genetic Predisposition to Disease; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Lipase; Lipid Metabolism; Loss of Function Mutation; Membrane Proteins; Methotrexate; Non-alcoholic Fatty Liver Disease; Polymorphism, Single Nucleotide; Toxicity Tests, Acute | 2021 |
Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Transaminases | 2018 |
Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Comorbidity; Cyclosporine; Etanercept; Female; Hepatitis B; Hepatitis C; Humans; Infliximab; Interleukin-17; Latent Tuberculosis; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Psoriasis; Ustekinumab | 2018 |
Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.
Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Case-Control Studies; Cohort Studies; Female; Humans; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Singapore | 2014 |
Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.
Topics: Animals; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Feces; Kidney; Liver; Male; Methotrexate; Multidrug Resistance-Associated Protein 2; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Tissue Distribution | 2014 |
Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Energy Metabolism; Folic Acid; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methotrexate; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats, Sprague-Dawley; Tissue Distribution | 2014 |
End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.
Topics: Aged; Body Mass Index; Cholangitis, Sclerosing; Diabetes Mellitus; End Stage Liver Disease; Female; Humans; Immunosuppressive Agents; Liver Diseases, Alcoholic; Liver Transplantation; Logistic Models; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Risk Factors; United States | 2014 |